Research advance in gastric neuroendocrine tumors.
10.11817/j.issn.1672-7347.2019.01.015
- Author:
Zhenjiang WANG
1
;
Yuxian GU
1
;
Yanxian REN
1
;
Keshen WANG
1
;
Zhijian MA
1
;
Zuoyi JIAO
1
Author Information
1. First Division of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China.
- Publication Type:Journal Article
- MeSH:
Gastrins;
Gastroscopy;
Humans;
Neuroendocrine Tumors;
Proton Pump Inhibitors;
Stomach Neoplasms
- From:
Journal of Central South University(Medical Sciences)
2019;44(1):92-99
- CountryChina
- Language:Chinese
-
Abstract:
Gastric neuroendocrine tumors are rarely seen in the gastric tumors, because there are few case reports and the clinical diagnosis rate is low. There is no consensus treatment method in the world. However, with the benefit of esophagogastrodenoscopy and widespread use of proton pump inhibitors, the diagnostic rate of gastric neuroendocrine tumors is on the increase, which gives us an updated understanding for the pathogenesis and pathophysiology of the disease. By studying its pathogenesis, scholars have found that hypergastrinemia caused by various causes is closely related to its occurrence. Gastric neuroendocrine tumors are classified into different types or pathological grades depending on the state of progression of the disease and the unique clinical manifestations. Clinically used diagnostic methods include gastroscopy, medical imageology, nuclear medicine, gastrin, CgA, etc. There are also differences in treatments depending on the clinical classification. If the disease progresses rapidly and the grade is high, surgical resection of the lesion plus postoperative adjuvant chemotherapy should be actively performed. Other better treatments are still being explored.
